139 related articles for article (PubMed ID: 24939418)
1. Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.
Xu W; Wei W; Yu Q; Wu C; Ye C; Wu Y; Yan H
Mol Med Rep; 2014 Sep; 10(3):1519-24. PubMed ID: 24939418
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Dai Y; Rahmani M; Pei XY; Dent P; Grant S
Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1.
Li QF; Yan J; Zhang K; Yang YF; Xiao FJ; Wu CT; Wang H; Wang LS
Biochem Biophys Res Commun; 2011 Feb; 405(1):31-6. PubMed ID: 21195056
[TBL] [Abstract][Full Text] [Related]
4. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
Yan H; Wang YC; Li D; Wang Y; Liu W; Wu YL; Chen GQ
Leukemia; 2007 Jul; 21(7):1488-95. PubMed ID: 17495969
[TBL] [Abstract][Full Text] [Related]
6. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
[TBL] [Abstract][Full Text] [Related]
7. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M
Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973
[TBL] [Abstract][Full Text] [Related]
8. [STI571 enhances the effect of arsenic trioxide and Velcade on bcr/abl+-CD34+ cell proliferation and apoptosis].
Li CY; Meng FY; Sun QX; Fu YB; Li L; Yi ZS; Song LL
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Nov; 27(11):1665-9. PubMed ID: 18024285
[TBL] [Abstract][Full Text] [Related]
9. Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.
Puccetti E; Beissert T; Güller S; Li JE; Hoelzer D; Ottmann OG; Ruthardt M
Oncogene; 2003 Oct; 22(44):6900-8. PubMed ID: 14534537
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
11. [Arsenic trioxide inhibits cell growth in imatinib-resistant bcr-abl mutant cell lines in vitro].
Lu RZ; Qiu L; Wang XD; Li XF; Chen LJ; Wang XL; Zhang BL; Ma J
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):13-7. PubMed ID: 19563028
[TBL] [Abstract][Full Text] [Related]
12. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
Greene LM; Kelly L; Onnis V; Campiani G; Lawler M; Williams DC; Zisterer DM
J Pharmacol Exp Ther; 2007 Apr; 321(1):288-97. PubMed ID: 17202400
[TBL] [Abstract][Full Text] [Related]
13. An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib.
Xing H; Liu T; Meng W; Gong Y
Int J Lab Hematol; 2011 Apr; 33(2):176-81. PubMed ID: 20942869
[TBL] [Abstract][Full Text] [Related]
14. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
15. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
Okabe S; Tauchi T; Ohyashiki K
Clin Cancer Res; 2008 Oct; 14(19):6181-6. PubMed ID: 18829496
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells.
Albero MP; Vaquer JM; Andreu EJ; Villanueva JJ; Franch L; Ivorra C; Poch E; Agirre X; Prosper F; Pérez-Roger I
Oncogene; 2010 Jun; 29(22):3276-86. PubMed ID: 20305692
[TBL] [Abstract][Full Text] [Related]
19. Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.
Ju DS; Kim MJ; Bae JH; Song HS; Chung BS; Lee MK; Kang CD; Lee HS; Kim DW; Kim SH
Cancer Lett; 2007 Jul; 252(1):75-85. PubMed ID: 17223257
[TBL] [Abstract][Full Text] [Related]
20. Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl.
Dasmahapatra G; Nguyen TK; Dent P; Grant S
Leuk Res; 2006 Oct; 30(10):1263-72. PubMed ID: 16481037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]